Biotech Software: Types, Categories, and How to Choose
Biotech software is the set of specialised platforms that run the life-sciences value chain — from laboratory data capture and bioinformatics analysis, through clinical trials and regulatory compliance, to manufacturing and secure data collaboration. It divides into eight working categories: laboratory informatics, electronic lab notebooks, bioinformatics platforms, clinical trial systems, regulatory and quality management, manufacturing execution, AI-driven discovery platforms, and federated data infrastructure such as the Trusted Research Environment (TRE). This guide explains what each category does, who buys it, and how to choose — with particular attention to the newest category, secure federated data infrastructure, which increasingly determines what every other system is allowed to do with sensitive data.
Why the biotech software stack matters now
Two shifts have turned software from back-office tooling into core biotech infrastructure. The first is data volume: modern sequencing, imaging, and high-throughput screening generate data at a scale no spreadsheet-era workflow survives — a single human genome is roughly 100 gigabytes of raw sequence data, and national programmes now hold hundreds of thousands of genomes. The second is regulation: GDPR, HIPAA, the EU AI Act, and the European Health Data Space (EHDS) — which requires secondary-use health data to be analysed within secure processing environments — mean that how software handles data is now a legal question, not just an engineering one. The May 2026 UK Biobank incident, in which approved researchers exported sensitive data through a centralised platform’s ordinary workflow, made the consequence concrete: architecture, not policy, is what actually constrains data. Buyers now evaluate every layer of the stack against that lesson.
The eight categories of biotech software
Laboratory informatics: LIMS and scientific data management
A Laboratory Information Management System (LIMS) tracks samples, tests, instruments, and results through the lab. It is the system of record for what was measured, on what material, by whom, and under which protocol — foundational for reproducibility and for any regulated (GxP) environment. Scientific data management systems (SDMS) sit alongside, capturing raw instrument output.
Electronic lab notebooks
An Electronic Lab Notebook (ELN) replaces the paper notebook: experiment design, observations, and conclusions, with timestamps and signatures that support intellectual-property claims and audit. ELN and LIMS increasingly converge into unified research-and-development (R&D) platforms.
Bioinformatics and genomics platforms
Bioinformatics platforms run the computational pipelines that turn raw sequencing output into scientific results — alignment, variant calling, annotation, and downstream statistics — usually on cloud or high-performance computing infrastructure, with workflow languages such as Nextflow and WDL providing reproducibility. The buying question here has changed: it is no longer only “can it run my pipeline?” but “can it run my pipeline where the data is allowed to live?”
Clinical trial systems
Clinical operations run on a family of systems: Clinical Trial Management Systems (CTMS) for planning and site management, Electronic Data Capture (EDC) for case report forms, and electronic clinical outcome assessment (eCOA) tools for patient-reported data. All are validated against Good Clinical Practice (GCP) requirements and regulatory expectations such as FDA 21 CFR Part 11 on electronic records and signatures.
Regulatory and quality management
Quality Management Systems (QMS) manage documents, training, deviations, and corrective actions; Regulatory Information Management (RIM) systems assemble and track submissions to agencies such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). These systems exist to make compliance demonstrable, not just achieved.
Manufacturing and supply
Manufacturing Execution Systems (MES) enforce electronic batch records and process control in Good Manufacturing Practice (GMP) facilities — critical for biologics and cell and gene therapies, where process is the product.
AI-driven discovery platforms
A newer category applies machine learning to discovery itself: protein-structure prediction, molecule generation, target identification, and biomarker discovery. These platforms are only as good as the data they can reach — which is precisely where they collide with privacy and sovereignty constraints, and why Sovereign AI approaches, in which models are trained without sensitive data leaving its custodian, are becoming a selection criterion rather than a curiosity.
Federated data infrastructure: the Trusted Research Environment
The final category governs how all the others touch sensitive human data. A Trusted Research Environment is a secure, audited workspace where approved researchers analyse sensitive data under controls aligned with frameworks such as the Five Safes; a federated TRE goes further by deploying the environment at each data custodian and dispatching compute to the data, so that data never leaves the source. Lifebit’s federated Trusted Research Environment is built on this pattern for national biobanks, governments, and pharma research networks. As health-data regulation tightens, the federated TRE is becoming the layer that decides what the bioinformatics platform may compute, what the AI platform may train on, and what any user may export.
Biotech software categories compared
| Category | What it does | Typical buyer | Key selection question |
|---|---|---|---|
| LIMS / SDMS | Sample, test, and instrument data management | Lab operations, QC labs | GxP readiness and instrument integration |
| ELN | Experiment documentation and IP evidence | R&D scientists | Usability — an unused ELN protects nothing |
| Bioinformatics platform | Sequencing and omics pipelines at scale | Computational biology teams | Can compute run where the data must stay? |
| CTMS / EDC / eCOA | Clinical trial operations and data capture | Clinical operations, CROs | Validation status and 21 CFR Part 11 support |
| QMS / RIM | Quality processes and regulatory submissions | Quality and regulatory affairs | Audit-trail depth and submission-format support |
| MES | Electronic batch records, GMP process control | Manufacturing sites | Fit to modality (biologics, cell and gene) |
| AI discovery platform | ML for targets, molecules, biomarkers | Discovery and data science leadership | What data can it lawfully reach and train on? |
| Federated TRE | Secure, federated analysis of sensitive data | Biobanks, governments, pharma data offices | Does data stay at source, with airlocked outputs? |
How the categories fit together in practice
Consider a genomic medicine programme of the kind run by national initiatives such as Genomics England. Sequencing data lands in a bioinformatics platform for processing; sample provenance lives in a LIMS; researcher access happens inside a TRE, where analysis is brought to the data rather than the data being distributed to analysts; and any clinical study built on the findings runs through CTMS and EDC systems under regulatory oversight. The federated TRE sits at the centre of this stack, not the edge: it is the environment through which the sensitive-data value of every other system is realised. The same pattern appears in pharma real-world evidence groups, where harmonised hospital data — mapped to common standards through data harmonisation — is analysed across sites federatedly rather than pooled into a warehouse the custodians would never approve.
Integration: the ninth category that is not a category
What binds the stack together is not another product but a set of interoperability standards, and buyers should treat support for them as a hard requirement in every procurement. Health Level Seven’s Fast Healthcare Interoperability Resources (FHIR) is the exchange standard for clinical data; the OMOP Common Data Model, maintained by the Observational Health Data Sciences and Informatics (OHDSI) community, is the analysis standard for observational research data; and the Global Alliance for Genomics and Health (GA4GH) publishes the standards that make genomic data and access interoperable across institutions. A system that speaks these standards natively can join a research network in weeks; one that exports proprietary formats becomes a permanent translation project. The practical test to put to any vendor is concrete: show us your FHIR interface in production, show us a completed OMOP mapping, and show us the application programming interfaces (APIs) your customers actually use — not the ones on the roadmap slide.
Common buying mistakes
Five mistakes recur across biotech software procurement. Buying point solutions without a data architecture — eight excellent systems that cannot exchange data produce a ninth project to integrate them; decide your data standards (FHIR for clinical data, OMOP for observational research data) before buying, not after. Ignoring validation cost — in GxP contexts, validating the software often costs more than licensing it; ask vendors for validation accelerator packs and audit histories. Treating security as a checkbox — a SOC 2 report tells you about the vendor’s processes, not about whether your data can be exported by an approved user on a normal Tuesday; ask architectural questions. Underestimating scientists’ tolerance for bad UX — shadow spreadsheets appear wherever official tools are slower than Excel. And deferring the sovereignty question — if your data partners, patient cohorts, or national regulators will not allow data to move, a stack designed around centralisation will hit a wall that no amount of contract negotiation removes. A federated TRE addresses this last risk by design rather than by exception.
What to do next
Map your organisation’s workflows against the eight categories and score each on three axes: regulatory exposure, data sensitivity, and integration burden. Fill regulated gaps first (quality, clinical, manufacturing), then rationalise research tooling around shared data standards, and evaluate the data-infrastructure layer before committing to AI platforms — because the federated TRE or equivalent secure environment you choose will define what your AI investments are allowed to learn from. For teams working with human health data across institutions, that evaluation should start with a simple architectural test: does the platform move data to compute, or compute to data? The second answer is the one regulators, custodians, and patients are converging on.
Frequently asked questions
What is biotech software?
Biotech software is the specialised software used across life-sciences research, development, and manufacturing — including LIMS, electronic lab notebooks, bioinformatics platforms, clinical trial systems, quality and regulatory systems, manufacturing execution systems, AI discovery platforms, and secure data infrastructure such as Trusted Research Environments.
What is the difference between a LIMS and an ELN?
A LIMS manages structured operational data — samples, tests, instruments, results — while an ELN documents the experimental narrative: hypotheses, methods, observations, and conclusions. Labs typically need both, and modern platforms increasingly combine them.
What is a Trusted Research Environment in the biotech stack?
A Trusted Research Environment (TRE) is a secure, audited workspace where approved researchers analyse sensitive data without being able to remove it. A federated TRE deploys this environment at each data custodian and sends compute to the data, so patient-level records never move between institutions.
Which regulations most affect biotech software choices?
The main ones are GxP validation expectations and FDA 21 CFR Part 11 for regulated records, GDPR and HIPAA for personal health data, the EHDS for secondary use of health data in Europe, and the EU AI Act for AI systems used in high-risk contexts.
Should biotech companies build or buy their software?
Buy for regulated, commodity workflows (quality, clinical data capture, LIMS) where validation burden dominates; build only where the workflow is genuinely differentiating, such as proprietary analysis pipelines. Data infrastructure sits in between — most organisations buy the platform and configure the governance.
Why does federated infrastructure matter for AI in biotech?
The most valuable training data — hospital records, national cohorts, partner datasets — usually cannot be centralised for legal or commercial reasons. Federated infrastructure lets models train against that data where it lives, so AI programmes are not limited to the data that happens to be movable.